Table 1 Clinical characteristics of patients with colorectal cancer who performed a CALPRO® faecal calprotectin (FC) test within three months prior to diagnosis (n = 124)

Mean age, years (SD)

68 (11)

Gender

 Women

44% (n = 55)

 Men

56% (n = 69)

Colorectal cancer diagnosed at:

 Colonoscopy

92% (n = 114)

 Imaging

6% (n = 7)

 Surgery

2% (n = 3)

Median F-calprotectin level (μg/g) (25^th-75^th percentile)

149 (67–392)

Proportion of patients with:

 F-calprotectin ≥ 50 μg/g

79% (n = 98)

 F-calprotectin ≥ 100 μg/g

60% (n = 74)

 Positive faecal immunchemical test (n = 76)^a

89% (n = 68)

Tumor characteristics (n = 108)^a

 Low-grade

85% (n = 92)

 High-grade

15% (n = 16)

 Non-Mucinous

85% (n = 92)

 Mucinous

15% (n = 16)

 Vascular invasion (n = 103)^a

18% (n = 19)

 Perineural growth (n = 103)^a

19% (n = 20)

TNM classification

Tumor (T) (n = 109)^a

 T1

3% (n = 3)

 T2

19% (n = 21)

 T3

61% (n = 66)

 T4a

9% (n = 10)

 T4b

8% (n = 9)

Nodes (N) (n = 106)^a

 N0

49% (n = 54)

 N1

25% (n = 29)

 N2

20% (n = 23)

Metastasis (M):

 M0

80% (n = 99)

 M1

20% (n = 25)

Tumor Stage

 I

20% (n = 24)

 II

28% (n = 35)

 III

32% (n = 40)

 IV

20% (n = 25)

Tumor localization

 Right colon

23% (n = 29)

 Transverse colon

6% (n = 7)

 Left colon

29% (n = 36)

 Rectum

42% (n = 52)

Median values (25th-75th percentile) of:

 C-reactive protein (mg/L) (n = 100)^a

4.5 (1.5–13)

 B-haemoglogin (g/L) (n = 121)^a

133 (108–142)

 Mean corpuscular volume (fL) (n = 121)^a

88 (82–92)

 Serum carcinoembryogenic antigen (μg/L) (n = 116)^a

3.1 (1.8–6.9)

 Serum ferritin (μg/L) (n = 48)^a

42 (13–88)